Researchers and a specialty pharmaceutical company have taken a longstanding theory about addiction and have used it to develop a novel approach to its treatment with medication, in the hope of creating the breakthrough drug for patients with cocaine dependence.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that EMB-001 was found to be well-tolerated in a Phase 1b cocaine interaction study, and no new safety signals were observed.
Robert Linke, Embera’s president and CEO, spoke with CEOCFO Magazine regarding Embera’s new approach to treating addictions and how attitudes toward addiction are evolving.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that it has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”
Robert Linke, president and CEO of Embera Neurotherapeutics, a specialized biopharmaceutical firm based in Shreveport, Louisiana spoke with Drug Discovery & Development via email about his company’s progress on the development of drugs that battle addiction.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine use disorder, smoking cessation, and other addictions, today announced that EMB-001 met the primary endpoints of safety and tolerability in a Phase 1 clinical trial. Embera also announced that the Company’s Chief Executive Officer, Robert Linke and Chief Medical Officer, Dr. Michael Detke, will present at the Biotech Showcase on Monday, January 11, 2016 at 2:30pm in San Francisco, California.
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced the first subject received the initial dose in a Phase 1 clinical trial evaluating EMB-001. A novel combination of the FDA-approved drugs metyrapone and oxazepam, EMB-001 is being investigated for the potential treatment of cocaine use disorder and other addictions such as tobacco and methamphetamine use disorders.